Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health — Q3 2019 Earnings Presentation
14 slides from Vireo Growth's earnings presentation, Nov 27, 2019
Slide 1: Q3 2019 Earnings Conference Call
“We are building the cannabis company of the future by bringing the best of science, medicine and engineering to the cannabis industry.” Q3 2019 Earnings Conference Call November 27, 2019 - Kyle Kingsley, M.D. CNSX: VREO OTCQX: VREOF Founder & CEO
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward- looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-l
Slide 3: Today's Presenters
Today’s Presenters Kyle Kingsley, M.D. Founder & Chief Executive Officer Dial-in & Webcast Details: Dial-ins: 866-211-3165 (Toll-Free) B647-689-6580 (International) .BID 5293509 Amber Shimpa Chief Financial Officer Webcast Link: https://event.on24.com/wcc/r/2083534/A194 133AD818005924500C659E39240F
Slide 4: Vireo Welcomes Bruce Linton
Vireo Welcomes Bruce Linton Vireo Welcomes Bruce Linton || 4
Slide 5: Business Highlights
Business Highlights • Vireo generated revenue in seven states in the third quarter 2019: Minnesota, New York, Pennsylvania, Maryland, Arizona, New Mexico, and Ohio. • Third quarter revenue increased 62 percent year-over- year to $8.0 million, driven by increasing demand and patient counts across mos
Slide 6: New Product Development & Marketing Update
New Product Development & Marketing Update Pharmaceutical-grade Products Innovative soft gels that delivers Premium-grade cannabis A microdose of cannabis in a Geared Toward Patients consistent and precise doses for handpicked, hand-packaged, and traditional pre-roll, offering the the desired effect
Slide 7: Green Goods Retail Dispensaries: Best-in-Class Customer Experience
Best-in-Class Green Goods™ Customer Experience:Now Open Retail Dispensaries Retail Dispensaries Green Goods™ Retail Concept Caters to Complete Cannabis Consumer Spectrum (images reflect the build-out of our Bethlehem, PA location) Q3FY18 2019Results ResultsConference ConferenceCall Call|||| 77
Slide 8: Key Third Quarter 2019 Financial Metrics
Key Third Quarter 2019 Financial Metrics Three Months Ended Nine Months Ended September 30, September 30, $ in millions, except per share data 2019 2018 Variance 2019 2018 Variance Revenue $8.0 $4.9 $3.1 $21.0 $12.8 $8.1 Gross Profit (Before Fair Value Adjustments) $1.3 $2.9 ($1.6) $6.5 $7.2 ($0.6)
Slide 9: Third Quarter 2019 Performance
Third Quarter 2019 Performance • Total revenue for the third quarter of 2019 increased 62 percent year-over-year to $8.0 million. • Revenue growth was driven by increasing demand and patient counts across most markets, continued wholesale market growth, and contributions from acquired entities in Ar
Slide 10: Manufacturing Update
Manufacturing Update Expected Operating Footprint Entering Fiscal Year 2020* Minnesota New York Pennsylvania Maryland Arizona New Mexico Operational Cultivation 80,000 sq. ft. 53,000 sq. ft. 9,000 sq. ft. 60,000 sq. ft. 10,000 sq. ft. 90,000 sq. ft. greenhouse / greenhouse/ warehouse/ warehouse ware
Slide 11: Slide 11
Slide 12: Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Consolidated Statements of Income (Loss) and Vireo Health, Inc. Consolidated Statements of Loss and Comprehensive Loss Comprehensive Income (Loss) For the Three Months Ended September 30, 2019 and 2018 (Expressed in United States Dollars) Three Month Three Month Period Ended Period Ended September 3
Slide 13: Consolidated Statements of Financial Position
Vireo Health, Inc. Consolidated Statements of Financial Position Consolidated Statements of Financial Position September 30, 2019 and December 31, 2018 (Expressed in United States Dollars) September 30, December 31, 2019 2018 ASSETS Current Assets Cash $ 16,362,708 $ 9,624,110 Receivables 1,865,301
Slide 14: Reconciliation of IFRS to Non-IFRS Financial Measures
Reconciliation of IFRS to Non-IFRS Financial Measures Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Net income (loss) $ (14,565,506) $ 14,890 $ (19,884,720) $ (1,894,732) Net fair value adjustments 9,665,610 (2,120,091) 704,467 (4,236,040) Listing expense - - 3